Target Price | $13.25 |
Price | $6.13 |
Potential |
116.15%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Atara Biotherapeutics Inc 2026 .
The average Atara Biotherapeutics Inc target price is $13.25.
This is
116.15%
register free of charge
$18.00
193.64%
register free of charge
$7.00
14.19%
register free of charge
|
|
A rating was issued by 6 analysts: 4 Analysts recommend Atara Biotherapeutics Inc to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Atara Biotherapeutics Inc stock has an average upside potential 2026 of
116.15%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 128.94 | 76.75 |
1,404.55% | 40.48% | |
EBITDA Margin | -58.66% | -23.45% |
98.10% | 60.02% | |
Net Margin | -51.86% | -44.13% |
98.84% | 14.90% |
6 Analysts have issued a sales forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Atara Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Atara Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -11.41 | -5.78 |
82.49% | 49.34% | |
P/E | negative | |
EV/Sales | 1.01 |
2 Analysts have issued a Atara Biotherapeutics Inc forecast for earnings per share. The average Atara Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Atara Biotherapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jan 17 2025 |
Rodman & Renshaw |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 21 2024 |
Analyst Rating | Date |
---|---|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 22 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jan 17 2025 |
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
Dec 20 2024 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 13 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 21 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.